List of Excipients in Branded Drug ZELAPAR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	ZELAPAR	selegiline hydrochloride	0187-0453	ASPARTAME
Bausch Health US LLC	ZELAPAR	selegiline hydrochloride	0187-0453	CITRIC ACID MONOHYDRATE
Bausch Health US LLC	ZELAPAR	selegiline hydrochloride	0187-0453	FERRIC OXIDE YELLOW

ZELAPAR Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

ZELAPAR is a 1.25 mg selegiline hydrochloride orally disintegrating tablet for adjunctive treatment of Parkinson's disease. Its commercial differentiation depends on rapid oral disintegration, low-dose content uniformity, moisture protection, palatability, and avoidance of swallowing water. The principal opportunity is a low-cost generic or reformulated orally disintegrating selegiline product, but market size is limited by generic competition, selegiline's mature clinical profile, and safety restrictions associated with monoamine oxidase inhibition.

What is ZELAPAR and how does its formulation work?

ZELAPAR contains selegiline hydrochloride, a selective monoamine oxidase type B inhibitor used as an adjunct to levodopa/carbidopa in Parkinson's disease. The product is administered as a 1.25 mg orally disintegrating tablet placed on the tongue, where it dissolves without water.[1]

The formulation targets patients who have difficulty swallowing conventional tablets or who need a convenient administration format. ZELAPAR's formulation value is therefore delivery-related rather than based on a new active pharmaceutical ingredient.

Attribute	ZELAPAR profile
Active ingredient	Selegiline hydrochloride
Strength	1.25 mg
Dosage form	Orally disintegrating tablet
Route	Oral
Indication	Adjunct treatment of Parkinson's disease
Key formulation benefit	Rapid disintegration without water
Principal commercial constraint	Mature active ingredient and safety-limited use
Relevant regulatory pathway	Abbreviated New Drug Application for a generic equivalent

What excipients are used in ZELAPAR?

Public product information identifies a rapidly disintegrating excipient system that includes mannitol, citric acid, sodium citrate, aspartame, gelatin, and other formulation components used to support tablet structure and dissolution.[1,2]

The commercially relevant excipient functions are as follows:

Excipient or excipient class	Likely formulation function
Mannitol	Bulking agent, mouthfeel modifier, water-soluble diluent
Gelatin	Matrix-forming and structural component in a rapidly disintegrating tablet
Crospovidone or comparable disintegrant	Promotes rapid breakup when exposed to saliva
Citric acid	Taste adjustment, acidulant, microenvironmental pH control
Sodium citrate	Buffering and flavor balancing
Aspartame	Sweetener for taste masking
Flavoring agents	Reduction of bitter or metallic drug taste
Packaging desiccant and high-barrier blister	Moisture protection

The exact quantitative composition, manufacturing parameters, particle-size specifications, and process controls are not fully disclosed in the public label. Those parameters are likely more important to product performance than the excipient list alone.

How does the ZELAPAR excipient strategy create formulation value?

The formulation is built around four performance requirements.

Rapid wetting and disintegration

A ZELAPAR-type product must disperse rapidly in a small volume of saliva. Mannitol provides a soluble, relatively low-hygroscopic bulk matrix with a cooling mouthfeel. A superdisintegrant, if used, accelerates tablet breakup. Excessive compression force can reduce porosity and slow disintegration, so the manufacturing process must balance mechanical strength against rapid wetting.

Low-dose content uniformity

The 1.25 mg dose creates a high excipient-to-drug ratio. Small changes in drug distribution can materially affect dose uniformity. Commercial development therefore requires control of:

• Selegiline particle size and morphology
• Drug premix dilution
• Blend segregation
• Hopper residence time
• Tablet weight variation
• Assay and content uniformity

A generic developer cannot rely on conventional high-dose tablet process assumptions. The low drug load increases the value of ordered mixing, geometric dilution, or granulated intermediate strategies.

Taste masking

Selegiline can produce an unpleasant taste at the tongue. The product must dissolve quickly while limiting the duration of direct drug contact with taste receptors. Mannitol, aspartame, acidulant-buffer combinations, and flavors can reduce the perceived bitterness, but a replacement formula may require more robust taste-masking technology.

Potential commercial alternatives include:

• Ion-exchange resin complexes
• Polymer-coated drug particles
• Cyclodextrin complexes
• Lipid-based taste-masking systems
• Fast-dissolving oral films with flavor-control layers
• Microencapsulated selegiline particles

Each approach introduces additional manufacturing and regulatory risk. A simple excipient substitution is more attractive if it preserves rapid dissolution and sensory performance.

Moisture control

Rapidly disintegrating tablets are often moisture-sensitive. Water uptake can cause premature softening, loss of mechanical strength, slower disintegration, or chemical degradation. The packaging system is therefore part of the product strategy.

A commercial successor may use:

• Aluminum-aluminum blister packaging
• Unit-dose foil pouches
• Desiccant-containing bottles
• Low-moisture manufacturing conditions
• Tight water-activity specifications
• Stability testing under accelerated and long-term conditions

The packaging choice can affect distribution cost, patient convenience, and product robustness. A bottle may be cheaper but less protective and less suitable for a fragile ODT.

What formulations are protected by ZELAPAR-related intellectual property?

The core formulation concept is an orally disintegrating selegiline dosage form. Potentially protectable technical features include:

• Specific excipient ratios
• A freeze-dried or lyophilized tablet matrix
• A particular mannitol-gelatin structure
• Taste-masked selegiline particles
• Disintegration time under defined test conditions
• Moisture content and packaging configuration
• Manufacturing conditions that produce a specified porous structure

The original ZELAPAR formulation was associated with orally disintegrating tablet technology developed for fast-dissolving products. Product and platform patents may have covered the dosage form, manufacturing process, or specific excipient combinations. Those rights should be separated from any patent covering selegiline itself.

What is the Orange Book status of ZELAPAR?

ZELAPAR's active ingredient is old, and any original US formulation or product patents would generally be expected to have expired or to be near the end of their enforceable life. The commercial barrier is therefore more likely to be regulatory execution, formulation know-how, and market economics than a durable composition-of-matter patent.

The FDA Orange Book remains the controlling source for current listed patents, exclusivity, and therapeutic-equivalence information.[3] A launch assessment should review:

• Current NDA listing status
• Any remaining patent entries
• Patent delisting history
• Approved generic products
• Therapeutic-equivalence codes
• Withdrawal or discontinuation status

A developer should not assume that the absence of a visible commercial brand eliminates all formulation IP risk. Unlisted process, packaging, trade-secret, and know-how protections can still affect development economics.

When does ZELAPAR lose exclusivity?

Selegiline's active-ingredient exclusivity has expired. The relevant commercial question is whether any remaining product-specific patent, regulatory exclusivity, or market-access barrier prevents an ANDA launch.

For a mature small-molecule product such as ZELAPAR:

Exclusivity category	Commercial assessment
New chemical entity exclusivity	Expired
Active-ingredient patent protection	Expired
Orphan-drug exclusivity	Not the primary protection for ZELAPAR
Pediatric exclusivity	No current practical barrier expected
Formulation patent risk	Requires current Orange Book review
Generic approval pathway	ANDA, subject to reference-product availability and bioequivalence requirements
Market exclusivity	Limited by existing selegiline products and alternative dosage forms

Are Paragraph IV challenges relevant to ZELAPAR?

A Paragraph IV strategy could be relevant if a current Orange Book-listed patent remains associated with the reference product. An ANDA applicant may certify that the patent is invalid, unenforceable, or will not be infringed. That certification can trigger patent litigation and, if timely filed, a statutory 30-month stay of approval under the Hatch-Waxman framework.[4]

For ZELAPAR, the more likely development path is a Paragraph III or non-infringement strategy if no enforceable product patent remains. A Paragraph IV filing would be commercially rational only if:

1. The reference product has an active listed patent.
2. The expected market is large enough to justify litigation.
3. The proposed formulation can avoid infringement.
4. The applicant can establish bioequivalence despite the ODT format.
5. The product is commercially available as a reference for comparative testing.

The value of a first-filer position would depend on the existence of an eligible patent challenge and the remaining demand for the branded dosage form.

What FDA regulatory issues affect a generic ZELAPAR?

A generic developer would likely pursue an ANDA referencing the ZELAPAR product. The main technical requirements are bioequivalence, pharmaceutical equivalence, stability, manufacturing consistency, and comparative product performance.[5]

Key regulatory risks include:

Bioequivalence for an orally disintegrating tablet

The applicant may need to demonstrate that the product has the same active ingredient, strength, dosage form, route, and relevant performance characteristics. Depending on FDA requirements, in vivo pharmacokinetic testing may be required. Rapid dissolution alone does not establish bioequivalence.

Comparative dissolution

The dissolution method must discriminate between formulations. A product that disintegrates rapidly but releases selegiline differently from the reference could face additional regulatory questions.

Inactive-ingredient suitability

Excipients used in an oral product must be acceptable at the proposed levels. Aspartame creates a labeling consideration for patients with phenylketonuria. Gelatin raises source and supply-chain questions, including animal-origin documentation and potential market-specific restrictions.

Safety labeling

Selegiline has important interaction risks involving serotonergic drugs, meperidine, tramadol, certain antidepressants, and other monoaminergic medicines. The product label also contains dietary and dose-related warnings.[1] A generic applicant must preserve the relevant safety information and manage medication-use risks.

What commercial opportunities exist for ZELAPAR excipient innovation?

Low-cost generic ODT

The most direct opportunity is a generic selegiline ODT with a simpler, scalable formulation. A successful product would need to match reference-product performance while lowering manufacturing and packaging costs.

Potential advantages include:

• Direct substitution in pharmacy channels
• Lower unit manufacturing cost
• Improved supply reliability
• Simplified excipient sourcing
• Better moisture stability
• Competitive pricing against the branded product

Improved taste and patient adherence

A better-tasting product could target patients who discontinue or avoid orally disintegrating medicines because of bitterness. This is a formulation opportunity rather than a broad new-market opportunity. The clinical value would need to be supported by patient-preference or usability data.

Aspartame-free formulation

An aspartame-free product could address patients with phenylketonuria or patients seeking a different sweetener system. Alternatives include sucralose, acesulfame potassium, stevia-derived sweeteners, polyols, or taste-masked drug particles. The substitution must preserve dissolution, stability, and mouthfeel.

Vegan or animal-origin-free product

Replacing gelatin with pullulan, hypromellose, starch derivatives, or other polymers could support vegetarian, vegan, or selected international markets. The replacement may alter tablet strength, disintegration, friability, and moisture sensitivity.

Oral film or buccal delivery

A selegiline oral film could provide a differentiated administration format. The product would compete with existing oral and transdermal selegiline products and would face additional development requirements for dose uniformity, film adhesion, drying, packaging, and taste masking.

Pediatric or swallowing-difficulty positioning

Parkinson's disease is primarily an older-adult market, so swallowing convenience is commercially relevant. A more robust ODT or oral film could support use in patients with dysphagia, although the label, evidence base, and reimbursement position would determine the commercial value.

How does ZELAPAR compare with other selegiline products?

Product type	Main advantage	Main limitation
ZELAPAR ODT	Water-free administration and low dose	Limited market and ODT manufacturing complexity
Conventional oral selegiline tablet or capsule	Established, low-cost dosage form	Requires swallowing water
Emsam transdermal system	Avoids gastrointestinal oral administration and offers sustained delivery	Patch cost, skin reactions, dietary and interaction considerations at higher doses
Oral film	Portable and potentially discreet	Taste masking, packaging, film uniformity, and regulatory complexity
Compounded liquid or alternative formulation	Flexible administration	Limited standardization and commercial scalability

ZELAPAR's competitive advantage is convenience, not superior pharmacology. The product must compete with conventional selegiline, transdermal selegiline, rasagiline, and other Parkinson's adjunctive therapies.

Which companies could challenge or commercialize a ZELAPAR alternative?

Potential participants include established generic manufacturers with ODT capabilities, specialty pharmaceutical companies, contract development and manufacturing organizations, and companies holding fast-dissolving dosage-form technology.

The strongest candidates would have:

• Existing selegiline or Parkinson's products
• ANDA experience
• ODT or oral-film manufacturing
• High-barrier blister packaging
• Taste-masking capability
• Low-dose content-uniformity expertise
• Commercial access to neurologists and specialty pharmacies

A small developer could license a platform technology and outsource manufacture. A larger generic company could pursue a direct ANDA strategy, but the limited market may constrain the number of serious entrants.

What generic launch risks exist for ZELAPAR?

The principal launch risks are commercial rather than patent-driven.

1. The reference product may have limited current sales or availability.
2. A small market may not support expensive clinical, formulation, and legal work.
3. ODT packaging can raise cost per dose.
4. The branded product may have been discontinued or commercially deprioritized.
5. Selegiline alternatives may capture demand.
6. Physicians may use conventional selegiline or rasagiline instead.
7. A formulation that is pharmaceutically equivalent may still perform poorly on taste or handling.
8. Supply disruptions involving gelatin, mannitol, sweeteners, or specialty packaging may delay launch.

A generic launch is most attractive when the developer can use an existing ODT platform, minimize new equipment, and secure multi-market registration.

What is the patent strength of the ZELAPAR estate?

ZELAPAR's patent strength is likely weak as a blocking estate if the relevant product and platform patents have expired. The remaining value is more likely to reside in confidential manufacturing parameters, supplier relationships, analytical methods, and packaging controls.

A practical strength assessment is:

IP category	Likely current strength
Selegiline composition of matter	None
Basic oral selegiline use	Limited or expired
ODT dosage-form concept	Likely weak against modern generic development
Specific formulation claims	Depends on surviving patents and claim scope
Manufacturing know-how	Potentially meaningful but confidential
Packaging configuration	Usually limited unless tied to a specific patent claim
Trademark and branding	Separate from formulation exclusivity

Key Takeaways

• ZELAPAR is a 1.25 mg selegiline hydrochloride orally disintegrating tablet.
• Its formulation value comes from rapid disintegration, taste management, low-dose uniformity, and moisture protection.
• Mannitol, gelatin, sweetener, acidulant, buffer, and disintegrant systems are central to product performance.
• A generic ODT is the clearest commercial opportunity.
• Aspartame-free, animal-origin-free, improved-taste, and oral-film products offer secondary differentiation.
• Selegiline's active-ingredient exclusivity has expired, making formulation execution more important than molecule-level patent protection.
• Current Orange Book entries, reference-product availability, and approved generic status must control the launch analysis.
• The market is constrained by mature therapy, competing selegiline products, rasagiline, transdermal delivery, and safety-related prescribing limits.
• A platform-enabled developer with existing ODT capacity has the strongest commercial position.

FAQs

Is ZELAPAR still commercially available?

Commercial availability can vary by country, wholesaler, and time. The FDA's current Drugs@FDA record, Orange Book, and manufacturer supply information control the US status.[3,6]

Can ZELAPAR be reformulated without gelatin?

Yes. Gelatin can potentially be replaced with pullulan, hypromellose, starch-based polymers, or other matrix-forming excipients. The replacement must preserve rapid disintegration, mechanical integrity, stability, and bioequivalence.

Is an orally disintegrating selegiline product automatically bioequivalent to ZELAPAR?

No. The same strength and dosage-form description do not establish bioequivalence. The applicant must satisfy FDA requirements for pharmaceutical equivalence, performance, and, where required, pharmacokinetic comparison.

Does a selegiline oral film have stronger patent potential than a generic ZELAPAR tablet?

Potentially. A novel film architecture, taste-masking system, drug-loading method, or release profile could support new patent claims. Commercial value would depend on claim scope, clinical differentiation, and freedom to operate.

Which excipient is most commercially important in a ZELAPAR replacement?

No single excipient determines success. The highest-value system combines a soluble bulking agent, rapid-disintegration matrix, effective taste masking, low-dose mixing controls, and moisture-resistant packaging.

References

1. U.S. Food and Drug Administration. (2006). ZELAPAR (selegiline hydrochloride) orally disintegrating tablets prescribing information.
2. National Library of Medicine. (n.d.). Zelapar-selegiline hydrochloride tablet, orally disintegrating: DailyMed label.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
4. U.S. Food and Drug Administration. (2017). Approved drug products with therapeutic equivalence evaluations, 37th edition.
5. U.S. Food and Drug Administration. (2024). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA.
6. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.